Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

358 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels.
Santoro MM, Fabeni L, Armenia D, Alteri C, Di Pinto D, Forbici F, Bertoli A, Di Carlo D, Gori C, Carta S, Fedele V, D'Arrigo R, Berno G, Ammassari A, Pinnetti C, Nicastri E, Latini A, Tommasi C, Boumis E, Petrosillo N, D'Offizi G, Andreoni M, Ceccherini-Silberstein F, Antinori A, Perno CF. Santoro MM, et al. Among authors: bertoli a. Clin Infect Dis. 2014 Apr;58(8):1156-64. doi: 10.1093/cid/ciu020. Epub 2014 Jan 14. Clin Infect Dis. 2014. PMID: 24429430 Free article.
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy.
Santoro MM, Svicher V, Gori C, Zaccarelli M, Tozzi V, Forbici F, D'Arrigo R, Trotta MP, Bellocchi MC, Visco-Comandini U, Cenci A, Bertoli A, Narciso P, Antinori A, Perno CF, Ceccherini-Silberstein F. Santoro MM, et al. Among authors: bertoli a. New Microbiol. 2006 Apr;29(2):89-100. New Microbiol. 2006. PMID: 16841549
Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.
Santoro MM, Alteri C, Ronga L, Flandre P, Fabeni L, Mercurio F, D'Arrigo R, Gori C, Palamara G, Bertoli A, Forbici F, Salpini R, Boumis E, Tozzi V, Visco-Comandini U, Zaccarelli M, Van Houtte M, Pattery T, Narciso P, Antinori A, Ceccherini-Silberstein F, Perno CF. Santoro MM, et al. Among authors: bertoli a. AIDS Res Hum Retroviruses. 2012 Oct;28(10):1285-93. doi: 10.1089/AID.2011.0142. Epub 2012 Apr 18. AIDS Res Hum Retroviruses. 2012. PMID: 22417570 Free PMC article.
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART.
Armenia D, Soulie C, Di Carlo D, Fabeni L, Gori C, Forbici F, Svicher V, Bertoli A, Sarmati L, Giuliani M, Latini A, Boumis E, Zaccarelli M, Bellagamba R, Andreoni M, Marcelin AG, Calvez V, Antinori A, Ceccherini-Silberstein F, Perno CF, Santoro MM. Armenia D, et al. Among authors: bertoli a. PLoS One. 2014 Aug 25;9(8):e105853. doi: 10.1371/journal.pone.0105853. eCollection 2014. PLoS One. 2014. PMID: 25153969 Free PMC article.
Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia.
Fabeni L, Berno G, Svicher V, Ceccherini-Silberstein F, Gori C, Bertoli A, Mussini C, Lichtner M, Zaccarelli M, Ammassari A, Pinnetti C, Cicalini S, Mastroianni CM, Andreoni M, Antinori A, Perno CF, Santoro MM. Fabeni L, et al. Among authors: bertoli a. J Clin Microbiol. 2015 Sep;53(9):2935-41. doi: 10.1128/JCM.00893-15. Epub 2015 Jul 1. J Clin Microbiol. 2015. PMID: 26135872 Free PMC article.
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA.
Zaccarelli M, Santoro MM, Armenia D, Borghi V, Gennari W, Gori C, Forbici F, Bertoli A, Fabeni L, Giannetti A, Cicalini S, Bellagamba R, Andreoni M, Mastroianni CM, Mussini C, Ceccherini-Silberstein F, Perno CF, Antinori A. Zaccarelli M, et al. Among authors: bertoli a. J Clin Virol. 2016 Sep;82:94-100. doi: 10.1016/j.jcv.2016.07.007. Epub 2016 Jul 18. J Clin Virol. 2016. PMID: 27472519
Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment.
Armenia D, Zaccarelli M, Borghi V, Gennari W, Di Carlo D, Giannetti A, Forbici F, Bertoli A, Gori C, Fabeni L, Pinnetti C, Marocco R, Latini A, Ceccherini-Silberstein F, Mastroianni CM, Mussini C, Antinori A, Perno CF, Santoro MM. Armenia D, et al. Among authors: bertoli a. J Clin Virol. 2018 Jul;104:61-64. doi: 10.1016/j.jcv.2018.04.001. Epub 2018 Apr 3. J Clin Virol. 2018. PMID: 29738896
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice.
Alteri C, Scutari R, Bertoli A, Armenia D, Gori C, Fabbri G, Mastroianni CM, Cerva C, Cristaudo A, Vicenti I, Bruzzone B, Zazzi M, Andreoni M, Antinori A, Svicher V, Ceccherini-Silberstein F, Perno CF, Santoro MM. Alteri C, et al. Among authors: bertoli a. Virus Genes. 2019 Jun;55(3):290-297. doi: 10.1007/s11262-019-01649-z. Epub 2019 Feb 22. Virus Genes. 2019. PMID: 30796743
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen.
Armenia D, Di Carlo D, Cozzi-Lepri A, Calcagno A, Borghi V, Gori C, Bertoli A, Gennari W, Bellagamba R, Castagna A, Latini A, Pinnetti C, Cicalini S, Saracino A, Lapadula G, Rusconi S, Castelli F, Di Giambenedetto S, Andreoni M, Di Perri G, Antinori A, Mussini C, Ceccherini-Silberstein F, Monforte AD, Perno CF, Santoro MM; ICONA Foundation Study Group. Armenia D, et al. Among authors: bertoli a. Antivir Ther. 2019;24(5):321-331. doi: 10.3851/IMP3309. Antivir Ther. 2019. PMID: 30977466 Free article.
358 results